Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Multicenter, Subject and Sponsor-blinded, Placebo Controlled Study to Compare the Efficacy and Safety of "Anagrelide Retard" Versus Placebo in "at Risk" Subjects With Essential Thrombocythaemia

NCT01230775 is registered in ClinicalTrials.gov with AOP Orphan Pharmaceuticals AG as lead sponsor.

NCT NCT01230775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01230775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Multicenter, Subject and Sponsor-blinded, Placebo Controlled Study to Compare the Efficacy and Safety of "Anagrelide Retard" Versus Placebo in "at Risk" Subjects With Essential Thrombocythaemia
Lead sponsor
AOP Orphan Pharmaceuticals AG
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2010
Completion date
January 31, 2015
Enrollment
146 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

essential thrombocythaemia